[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201201452A1 - Терапевтические композиции - Google Patents

Терапевтические композиции

Info

Publication number
EA201201452A1
EA201201452A1 EA201201452A EA201201452A EA201201452A1 EA 201201452 A1 EA201201452 A1 EA 201201452A1 EA 201201452 A EA201201452 A EA 201201452A EA 201201452 A EA201201452 A EA 201201452A EA 201201452 A1 EA201201452 A1 EA 201201452A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic compositions
angela
ingenol
stabilized
dissolving
Prior art date
Application number
EA201201452A
Other languages
English (en)
Other versions
EA024152B1 (ru
Inventor
Марк Барри Браун
Майкл Эдвард Дональд Кродерз
Тахир Назир
Original Assignee
Пеплин Рисерч Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пеплин Рисерч Пти Лтд. filed Critical Пеплин Рисерч Пти Лтд.
Publication of EA201201452A1 publication Critical patent/EA201201452A1/ru
Publication of EA024152B1 publication Critical patent/EA024152B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ангелат ингенола представляет собой эффективное средство против злокачественной опухоли, и его можно стабилизировать растворением в апротонном растворителе в присутствии кислого буфера.
EA201201452A 2005-12-16 2006-12-18 Композиция для местного введения для лечения или профилактики рака кожи EA024152B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525680.5A GB0525680D0 (en) 2005-12-16 2005-12-16 Therapeutic compositions

Publications (2)

Publication Number Publication Date
EA201201452A1 true EA201201452A1 (ru) 2013-07-30
EA024152B1 EA024152B1 (ru) 2016-08-31

Family

ID=35736297

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200870063A EA018545B1 (ru) 2005-12-16 2006-12-18 Терапевтические композиции
EA201201452A EA024152B1 (ru) 2005-12-16 2006-12-18 Композиция для местного введения для лечения или профилактики рака кожи

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200870063A EA018545B1 (ru) 2005-12-16 2006-12-18 Терапевтические композиции

Country Status (22)

Country Link
US (13) US8278292B2 (ru)
EP (2) EP1988877B1 (ru)
JP (2) JP5484733B2 (ru)
KR (2) KR101593579B1 (ru)
AU (1) AU2006325244B2 (ru)
BR (1) BRPI0619919A2 (ru)
CA (1) CA2634073C (ru)
CY (2) CY1115292T1 (ru)
DK (1) DK1988877T3 (ru)
EA (2) EA018545B1 (ru)
ES (1) ES2461315T3 (ru)
GB (1) GB0525680D0 (ru)
HU (1) HUE020998T4 (ru)
IL (2) IL192221A (ru)
MX (1) MX2008007685A (ru)
NO (1) NO344271B1 (ru)
NZ (1) NZ569197A (ru)
PL (1) PL1988877T3 (ru)
PT (1) PT1988877E (ru)
SI (1) SI1988877T1 (ru)
WO (1) WO2007068963A2 (ru)
ZA (1) ZA200805187B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
NZ583157A (en) 2004-12-13 2011-12-22 Leo Lab Ltd Treatment of solid cancers with angeloyl substituted ingenanes
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
PL2152261T3 (pl) * 2007-04-30 2016-06-30 Leo Laboratories Ltd Leczenie zmian wywołanych przez wirusy
RU2572618C2 (ru) 2010-04-16 2016-01-20 Лео Фарма А/С Кристаллический ингенол мебутат
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
CN103443066A (zh) * 2010-12-22 2013-12-11 利奥实验室有限公司 巨大戟二萜醇-3-酰化物i
ES2659739T3 (es) 2010-12-22 2018-03-19 Leo Laboratories Limited 3-acilatos III de ingenol y 3-carbamatos de ingenol
BR112013015859A2 (pt) 2010-12-22 2018-11-21 Leo Laboratories Ltd composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
US20140350101A1 (en) * 2011-12-12 2014-11-27 Leo Laboratories Limited Gel compositions
US20140343141A1 (en) * 2011-12-12 2014-11-20 Leo Laboratories Limited Topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture
US20140350120A1 (en) * 2011-12-12 2014-11-27 Leo Laboratories Limited Topical composition comprising an ingenol derivative and an oily solvent
US20130251782A1 (en) 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20150133543A1 (en) * 2012-06-08 2015-05-14 Leo Laboratories Limited Topical gel composition comprising an ingenol derivative and a solvent mixture
WO2014001215A2 (en) 2012-06-26 2014-01-03 Leo Laboratories Limited 3-o-heteroaryl-ingenol
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
EP2931246A1 (en) * 2012-12-12 2015-10-21 Leo Laboratories Limited Gel compositions
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
JP6026335B2 (ja) * 2013-03-26 2016-11-16 日本メナード化粧品株式会社 油性固形粉末化粧料
WO2014161891A1 (en) 2013-04-02 2014-10-09 Leo Pharma A/S Ingenol mebutate in combination with laser therapy for the treatment of hyperkeratotic skin lesions
US20160120835A1 (en) * 2013-06-12 2016-05-05 Leo Laboratories Limited A topical composition
EP3060210A1 (en) * 2013-10-25 2016-08-31 Leo Laboratories Limited A method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
US9526714B2 (en) 2014-03-24 2016-12-27 Leo Laboratories Limited Method for treating skin lesions with ingenol mebutate
CN107510651A (zh) * 2016-06-17 2017-12-26 王成 一种小分子免疫药物的纳米靶向制剂制备及其用途
RU2648230C1 (ru) * 2017-02-21 2018-03-22 Общество с ограниченной ответственностью "М9" Гель антисептический ранозаживляющий с пролонгированным действием
BR112020011475B1 (pt) 2017-12-26 2023-05-16 Dow Global Technologies Llc Método para produzir um polímero à base de etileno multimodal
CN111208034A (zh) * 2018-11-21 2020-05-29 中昊晨光化工研究院有限公司 一种测定石蜡在有机溶剂中溶解度的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3805965A1 (de) 1988-02-25 1989-09-07 Tamas Geb Szenasi Eszter Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
RU2028808C1 (ru) * 1993-06-29 1995-02-20 Игорь Александрович Бойко Способ лечения онкологических заболеваний
US6080393A (en) * 1994-07-09 2000-06-27 Johnson & Johnson Consumer Products, Inc. Skin care composition comprising a retinoid
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US20040131665A1 (en) * 1999-10-22 2004-07-08 Wepfer Scott T. Topical anesthetic formulation
US6828346B2 (en) 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
AU5070100A (en) * 2000-05-22 2001-12-03 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20080095806A1 (en) * 2002-11-20 2008-04-24 Bathurst Ian C Composition And Method For Treating Inflammatory Diseases Using Protease Inhibitors
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
NZ583157A (en) * 2004-12-13 2011-12-22 Leo Lab Ltd Treatment of solid cancers with angeloyl substituted ingenanes
CA2629337A1 (en) 2005-11-14 2007-05-18 Peplin Research Pty Ltd Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
KR101914460B1 (ko) 2010-07-20 2018-11-05 레오 라보라토리즈 리미티드 인게놀-3-안젤레이트의 제조방법

Also Published As

Publication number Publication date
HUE020998T4 (hu) 2016-06-28
JP5484733B2 (ja) 2014-05-07
CY1115292T1 (el) 2017-01-04
JP2009519314A (ja) 2009-05-14
GB0525680D0 (en) 2006-01-25
KR20080092373A (ko) 2008-10-15
IL192221A0 (en) 2008-12-29
EP1988877B1 (en) 2014-02-12
US20160263067A1 (en) 2016-09-15
SI1988877T1 (sl) 2014-06-30
NZ569197A (en) 2011-11-25
US20130225677A1 (en) 2013-08-29
US20130225678A1 (en) 2013-08-29
US8372828B2 (en) 2013-02-12
US20160263068A1 (en) 2016-09-15
KR20140088617A (ko) 2014-07-10
CA2634073C (en) 2013-11-19
US9861603B2 (en) 2018-01-09
NO344271B1 (no) 2019-10-21
MX2008007685A (es) 2008-09-26
JP5709826B2 (ja) 2015-04-30
US20120295970A1 (en) 2012-11-22
US20130158110A1 (en) 2013-06-20
WO2007068963A2 (en) 2007-06-21
AU2006325244B2 (en) 2013-03-28
US8377919B2 (en) 2013-02-19
EA024152B1 (ru) 2016-08-31
EA018545B1 (ru) 2013-08-30
US9603822B2 (en) 2017-03-28
JP2013049715A (ja) 2013-03-14
KR101593579B1 (ko) 2016-02-15
DK1988877T3 (da) 2014-05-12
IL245513A0 (en) 2016-06-30
EP1988877A2 (en) 2008-11-12
US9833429B2 (en) 2017-12-05
PL1988877T3 (pl) 2014-07-31
PT1988877E (pt) 2014-04-29
KR101451993B1 (ko) 2014-10-22
US8716271B2 (en) 2014-05-06
US20140357712A1 (en) 2014-12-04
CY2014030I1 (el) 2020-05-29
WO2007068963A3 (en) 2007-11-01
US20160263070A1 (en) 2016-09-15
EP2399571A1 (en) 2011-12-28
US8372827B2 (en) 2013-02-12
NO20083150L (no) 2008-09-08
US9820959B2 (en) 2017-11-21
US20120295971A1 (en) 2012-11-22
US20160263069A1 (en) 2016-09-15
US20090292017A1 (en) 2009-11-26
US20180289654A1 (en) 2018-10-11
US9833428B2 (en) 2017-12-05
IL192221A (en) 2016-05-31
AU2006325244A1 (en) 2007-06-21
US8278292B2 (en) 2012-10-02
ZA200805187B (en) 2009-04-29
ES2461315T3 (es) 2014-05-19
EA200870063A1 (ru) 2009-02-27
CA2634073A1 (en) 2007-06-21
BRPI0619919A2 (pt) 2011-10-25
US20120309827A1 (en) 2012-12-06
US8735375B2 (en) 2014-05-27
US8536163B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
EA201201452A1 (ru) Терапевтические композиции
LTPA2016032I1 (lt) Hipoglikeminių agentų skyrimo būdai
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
IL258880A (en) Diarylhydantoin compounds
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
EP2019825A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
DK1863839T3 (da) Acylerede GLP-1-forbindelser
ATE528007T1 (de) Lagerstabile infusionslösung von dihydropteridinonen
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
PL2172211T3 (pl) Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
CR9672A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
EP2029135A4 (en) Epoxide inhibitors of cysteine proteases
DE602006010612D1 (de) Nadelinjektor
CR9300A (es) Uso de compuestos de hierro (iii)
EP1908459A4 (en) COMPOSITION FOR THE PREVENTION OF CANCER
ATE420949T1 (de) Impfstoff der einen attenuierten pestivirus enthält
EP1968442A4 (en) In situ hyperpolarization of imaging agents
EP1877420A4 (en) COMBINATION THERAPY IN THE TREATMENT OF CANCER
DK1742685T3 (da) Kanylepumpe
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU